Exclusive

Publication

Byline

India monitors evolving Gulf situation, 24x7 support given for nationals abroad: Additional Secretary Aseem R Mahajan

New Delhi, March 25 -- The Central government is closely monitoring the evolving situation in the Gulf region, with authorities maintaining constant coordination to ensure the safety and well-being of... Read More


Australian duo Marcus Stoinis, Cooper Connolly join Punjab Kings squad in Mohali

Chandigarh, March 25 -- Punjab Kings' Australian stars Marcus Stoinis and Cooper Connolly have officially joined the squad in Mohali. The duo arrived earlier on Wednesday to link up with the rest of t... Read More


Indonesia sees better-managed Eid travel in 2026: Cabinet Secretary

Jakarta, March 25 -- Indonesia has recorded notable improvements in the control, management, and safety of Eid al-Fitr homecoming travels this year, with achievements meeting President Prabowo Subiant... Read More


4-day work week, no AC: A look at countries hit by energy crisis amid West Asia war

India, March 25 -- The ongoing war between Iran and the United States has sent the entire world into disarray by triggering a global energy crisis. While the missiles and drones may be flying in the s... Read More


Millions left waiting as Nepal's driving licence backlog drags on

Kathmandu, March 25 -- Nearly 2.7 million people who cleared their driving licence tests are still waiting for their cards, years after completing the process, exposing deep inefficiencies in Nepal's ... Read More


Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More


Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More